rspНаучно-практическая ревматологияRheumatology Science and Practice1995-44841995-4492IMA-PRESS, LLC10.47360/1995-4484-2020-544-549rsp-2958Research ArticleОБЗОРЫ И ЛЕКЦИИREVIEWS AND LECTURESПервичная гипертрофическая остеоартропатияPrimary hypertrophic osteoarthropathyhttps://orcid.org/0000-0003-4168-7219ТрисветоваЕ. Л.TrisvetovaE. L.

Трисветова Евгения Леонидовна

220116, Минск, пр. Дзержинского, д. 83

Evgenia L. Trisvetova

220116, Minsk, Dzerzhinsky Ave., 83

trisvet-47@mail.ruУО «Белорусский государственный медицинский университет»БеларусьBelarusian State Medical UniversityBelarus202009112020585544549Copyright © Трисветова Е.Л., 20202020Трисветова Е.Л.Trisvetova E.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://rsp.mediar-press.net/rsp/article/view/2958

Представлены сведения о редком наследственном заболевании – первичной гипертрофической остеоартропатии с аутосомно-доминантным и аутосомно-рецессивным наследованием. Генетическая гетерогенность обусловливает клинический полиморфизм симптомов, появляющихся в детском и подростковом возрасте. Дифференциальную диагностику необходимо проводить со вторичной гипертрофической остеоартропатией, встречающейся в 90% случаев и ассоциированной со злокачественными новообразованиями, ревматическими болезнями и другими заболеваниями. Важное значение отводится рентгенологическим признакам, позволяющим уточнить локализацию, протяженность и характер поражения костей. Специфическое лечение заболевания отсутствует.

The article presents information about a rare hereditary disease – primary hypertrophic osteoarthropathy with autosomal dominant and autosomal recessive inheritance. Genetic heterogeneity is responsible for the clinical polymorphism of symptoms that appear in childhood and adolescence. Differential diagnosis should be carried out with secondary hypertrophic osteoarthropathy, which occurs in 90% of cases and is associated with malignant neoplasms, rheumatic diseases and other diseases. X-ray signs are of great importance to clarify the localization, extent and nature of bone lesions. There is no specific treatment for the disease.

гипертрофическая остеоартропатияпервичнаявторичнаядиагностикадифференциальная диагностикаhypertrophic osteoarthropathyprimarysecondarydiagnosisdifferential diagnosisReferencesCastori M., Sinibaldi L., Mingarelli R., et al. Pachydermoperiostosis: an update. Clin Genet. 2005;68(6):477–486. DOI: 10.1111/j.1399-0004.2005.00533.xCastori M., Sinibaldi L., Mingarelli R., et al. Pachydermoperiostosis: an update. Clin Genet. 2005;68(6):477–486. DOI: 10.1111/j.1399-0004.2005.00533.xZhang Z., Zhang C., Zhang Zh. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013;7(1):60–64. DOI: 10.1007/s11684-013-0246-6Zhang Z., Zhang C., Zhang Zh. Primary hypertrophic osteoarthropathy: an update. Front Med. 2013;7(1):60–64. DOI: 10.1007/s11684-013-0246-6Yap F.Y., Skalski M.R., Patel D.B., et al. Hypertrophic Osteoarthropathy: RadioGraphics. 2017;37(1):157–195. DOI: 10.1148/rg.2017160052Yap F.Y., Skalski M.R., Patel D.B., et al. Hypertrophic Osteoarthropathy: RadioGraphics. 2017;37(1):157–195. DOI: 10.1148/rg.2017160052Jajic I., Jajic Z. Prevalence of primary hypertrophic osteoarthropathy in selected population. Clin Exp Rheumatol. 1992;10(2):73.Jajic I., Jajic Z. Prevalence of primary hypertrophic osteoarthropathy in selected population. Clin Exp Rheumatol. 1992;10(2):73.Giancane G., Diggle C.P., Legger E.G., et al. Primary hypertrophic osteoarthropathy: an update on patient features and treatment. J Rheumatol. 2015;42(11):2211–2214. DOI: 10.3899/jrheum.150364Giancane G., Diggle C.P., Legger E.G., et al. Primary hypertrophic osteoarthropathy: an update on patient features and treatment. J Rheumatol. 2015;42(11):2211–2214. DOI: 10.3899/jrheum.150364Uppal S., Diggle C.P., Carr I.M., et al. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet. 2008;40(6):789–793. DOI: 10.1038/ng.153Uppal S., Diggle C.P., Carr I.M., et al. Mutations in 15-hydroxyprostaglandin dehydrogenase cause primary hypertrophic osteoarthropathy. Nat Genet. 2008;40(6):789–793. DOI: 10.1038/ng.153Sasaki T., Niizeki H., Shimizu A., et al. Identification of mutations in the prostaglandin transporter gene SLCO2A1 and its phenotype–genotype correlation in Japanese patients with pachydermoperiostosis. J Dermatol Sci. 2012;68(1):36–44. DOI: 10.1016/j.jdermsci.2012.07.008Sasaki T., Niizeki H., Shimizu A., et al. Identification of mutations in the prostaglandin transporter gene SLCO2A1 and its phenotype–genotype correlation in Japanese patients with pachydermoperiostosis. J Dermatol Sci. 2012;68(1):36–44. DOI: 10.1016/j.jdermsci.2012.07.008Zhang Z., He J.W., Fu W.Z., et al. Mutations in the SLCO2A1 gene and primary hypertrophic osteoarthropathy: a clinical and biochemical characterization. J Clin Endocrinol Metab. 2013;98(5):E923–933. DOI: 10.1210/jc.2012-3568Zhang Z., He J.W., Fu W.Z., et al. Mutations in the SLCO2A1 gene and primary hypertrophic osteoarthropathy: a clinical and biochemical characterization. J Clin Endocrinol Metab. 2013;98(5):E923–933. DOI: 10.1210/jc.2012-3568Treasure T. Hypertrophic pulmonary osteoarthropathy and the vagus nerve: an historical note. J R Soc Med. 2006;99(8):388–390. DOI: 10.1258/jrsm.99.8.388Treasure T. Hypertrophic pulmonary osteoarthropathy and the vagus nerve: an historical note. J R Soc Med. 2006;99(8):388–390. DOI: 10.1258/jrsm.99.8.388Yao Q., Altman R.D., Brahn E. Periostitis and hypertrophic pulmonary osteoarthropathy: report of 2 cases and review of the literature. Semin Arthritis Rheum. 2009;38(6):458–466. DOI: 10.1016/j.semarthrit.2008.07.001Yao Q., Altman R.D., Brahn E. Periostitis and hypertrophic pulmonary osteoarthropathy: report of 2 cases and review of the literature. Semin Arthritis Rheum. 2009;38(6):458–466. DOI: 10.1016/j.semarthrit.2008.07.001Seifert W., Kuhnisch J., Tuysuz B., et al. Mutations in the prostaglandin transporter encoding gene SLCO2A1 cause primary hypertrophic osteoarthropathy and isolated digital clubbing. Hum Mutat. 2012;33(4):660–664. DOI: 10.1002/humu.22042Seifert W., Kuhnisch J., Tuysuz B., et al. Mutations in the prostaglandin transporter encoding gene SLCO2A1 cause primary hypertrophic osteoarthropathy and isolated digital clubbing. Hum Mutat. 2012;33(4):660–664. DOI: 10.1002/humu.22042Diggle C.P., Parry D.A., Logan C.V., et al. Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. Hum Mutat. 2012;33(8):1175–1181. DOI: 10.1002/humu.22111Diggle C.P., Parry D.A., Logan C.V., et al. Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis. Hum Mutat. 2012;33(8):1175–1181. DOI: 10.1002/humu.22111Matucci-Cerinic M., Lotti T., Jajic I., et al. The clinical spectrum of pachydermoperiostosis (primary hypertrophic osteoarthropathy). Medicine. 1991;70(3):208–214.Matucci-Cerinic M., Lotti T., Jajic I., et al. The clinical spectrum of pachydermoperiostosis (primary hypertrophic osteoarthropathy). Medicine. 1991;70(3):208–214.Martínez-Lavín M., Pineda C., Valdez T., et al. Primary hypertrophic osteoarthropathy. Semin Arthritis Rheum. 1988;17(3):156–162. DOI: 10.1016/0049-0172(88)90017-0Martínez-Lavín M., Pineda C., Valdez T., et al. Primary hypertrophic osteoarthropathy. Semin Arthritis Rheum. 1988;17(3):156–162. DOI: 10.1016/0049-0172(88)90017-0Li S.-S., He G.-W., Fu W.-Z., et al. Clinical, Biochemical, and Genetic Features of 41 Han Chinese Families With Primary Hypertrophic Osteoarthropathy, and Their Therapeutic Response to Etoricoxib: Results From a Six-Month Prospective Clinical Intervention. J Bone Miner Res. 2017;32(8):1659–1666. DOI:10.1002/jbmr.3157Li S.-S., He G.-W., Fu W.-Z., et al. Clinical, Biochemical, and Genetic Features of 41 Han Chinese Families With Primary Hypertrophic Osteoarthropathy, and Their Therapeutic Response to Etoricoxib: Results From a Six-Month Prospective Clinical Intervention. J Bone Miner Res. 2017;32(8):1659–1666. DOI:10.1002/jbmr.3157Korsten P., Bohnenberger H., Vasko R. Hypertrophic osteoarhropathy presenting as inflammatory arthritis. Arthritis Rheumatol. 2015;67(11):3036. DOI: 10.1002/art.39272Korsten P., Bohnenberger H., Vasko R. Hypertrophic osteoarhropathy presenting as inflammatory arthritis. Arthritis Rheumatol. 2015;67(11):3036. DOI: 10.1002/art.39272Padula S.J., Broketa G., Sampieri A., et al. Increased collagen synthesis in skin fibroblasts from patients with primary hypertrophic osteoarthropathy. Evidence for trans activational regulation of collagen transcription. Arthritis Rheum. 1994;37(9):1386–1394. DOI: 10.1002/art.1780370918Padula S.J., Broketa G., Sampieri A., et al. Increased collagen synthesis in skin fibroblasts from patients with primary hypertrophic osteoarthropathy. Evidence for trans activational regulation of collagen transcription. Arthritis Rheum. 1994;37(9):1386–1394. DOI: 10.1002/art.1780370918Rana R.S., Wu J.S., Eisenberg R.L. Periosteal reaction. AJR Am J Roentgenol. 2009;193(4):W259–W272. DOI: 10.2214/AJR.09.3300Rana R.S., Wu J.S., Eisenberg R.L. Periosteal reaction. AJR Am J Roentgenol. 2009;193(4):W259–W272. DOI: 10.2214/AJR.09.3300Jajic Z., Jajic I., Nemcic T. Primary hypertrophic osteoarthropathy: clinical, radiologic, and scintigraphic characteristics. Arch Med Res. 2001;32(2):136–142. DOI: 10.1016/s0188-4409(01)00251-xJajic Z., Jajic I., Nemcic T. Primary hypertrophic osteoarthropathy: clinical, radiologic, and scintigraphic characteristics. Arch Med Res. 2001;32(2):136–142. DOI: 10.1016/s0188-4409(01)00251-xCapelastegui A., Astigarraga E., García-Iturraspe C. MR findings in pulmonary hypertrophic osteoarthropathy. Clin Radiol. 2000;55(1):72–75. DOI: 10.1053/crad.1999.0101Capelastegui A., Astigarraga E., García-Iturraspe C. MR findings in pulmonary hypertrophic osteoarthropathy. Clin Radiol. 2000;55(1):72–75. DOI: 10.1053/crad.1999.0101Santhosh S., Bhattacharya A., Bhadada S., et al. Three-phase skeletal scintigraphy in pachydermoperiostosis. Clin Nucl Med. 2011;36(12):e199–e201. DOI: 10.1097/RLU.0b013e3182291ee0Santhosh S., Bhattacharya A., Bhadada S., et al. Three-phase skeletal scintigraphy in pachydermoperiostosis. Clin Nucl Med. 2011;36(12):e199–e201. DOI: 10.1097/RLU.0b013e3182291ee0Aparici C.M., Bains S. Hypertrophic osteoarthropathy seen with NaF18 PET/CT bone imaging. Clin Nucl Med. 2011;36(10):928–929. DOI: 10.1097/RLU.0b013e31821a2728Aparici C.M., Bains S. Hypertrophic osteoarthropathy seen with NaF18 PET/CT bone imaging. Clin Nucl Med. 2011;36(10):928–929. DOI: 10.1097/RLU.0b013e31821a2728Bozzao F., Bernardi S., Dore F., et al. Hypertrophic osteoarthropathy mimicking a reactive arthritis: a case report and review of the literature. BMC Musculoscelet Disord. 2018;19:145. DOI: 10.1186/s12891-018-2068-9Bozzao F., Bernardi S., Dore F., et al. Hypertrophic osteoarthropathy mimicking a reactive arthritis: a case report and review of the literature. BMC Musculoscelet Disord. 2018;19:145. DOI: 10.1186/s12891-018-2068-9Diamond S., Momeni M. Primary hypertrophic osteoarthropathy in a patient with rheumatoid arthritis. J Clin Rheumatol. 2007;13(4):242–243. DOI: 10.1097/RHU.0b013e31812e00b3Diamond S., Momeni M. Primary hypertrophic osteoarthropathy in a patient with rheumatoid arthritis. J Clin Rheumatol. 2007;13(4):242–243. DOI: 10.1097/RHU.0b013e31812e00b3Armstrong D.J., McCausland E.M., Wright G.D. Hypertrophic pulmonary osteoarthropathy (HPOA) (Pierre Marie-Bamberger syndrome): two cases presenting as acute inflammatory arthritis. Description and review of the literature. Rheumatol Int. 2007;27(4):399–402. DOI: 10.1007/s00296-006-0224-2Armstrong D.J., McCausland E.M., Wright G.D. Hypertrophic pulmonary osteoarthropathy (HPOA) (Pierre Marie-Bamberger syndrome): two cases presenting as acute inflammatory arthritis. Description and review of the literature. Rheumatol Int. 2007;27(4):399–402. DOI: 10.1007/s00296-006-0224-2Aluoch A.O., Farbman M., Gladue H. An unusual mimicker of systemic lupus erythematosus: a case report. Open Rheumatol J. 2015;9:27–29. DOI: 10.2174/18743129014090100027Aluoch A.O., Farbman M., Gladue H. An unusual mimicker of systemic lupus erythematosus: a case report. Open Rheumatol J. 2015;9:27–29. DOI: 10.2174/18743129014090100027Shinjo S.K., Borba E., Goncalves C.R., et al. Ankylosing spondylitis in a patient with primary hypertrophic osteoarthropathy. J Clin Rheumatol. 2007;13(3):175. DOI: 10.1097/RHU.0b013e3180690b97Shinjo S.K., Borba E., Goncalves C.R., et al. Ankylosing spondylitis in a patient with primary hypertrophic osteoarthropathy. J Clin Rheumatol. 2007;13(3):175. DOI: 10.1097/RHU.0b013e3180690b97Ihde L.L., Forrester D.M., Gottsegen C.J., et al. Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. Radiographics. 2011;31(7):1865–1882. DOI: 10.1148/rg.317115093Ihde L.L., Forrester D.M., Gottsegen C.J., et al. Sclerosing bone dysplasias: review and differentiation from other causes of osteosclerosis. Radiographics. 2011;31(7):1865–1882. DOI: 10.1148/rg.317115093Pineda C., Martínez-Lavín M. Hypertrophic osteoarthropathy: what a rheumatologist should know about this uncommon condition. Rheum Dis Clin. North Am. 2013;39(2):383–400. DOI: 10.1016/j.rdc.2013.02.008Pineda C., Martínez-Lavín M. Hypertrophic osteoarthropathy: what a rheumatologist should know about this uncommon condition. Rheum Dis Clin. North Am. 2013;39(2):383–400. DOI: 10.1016/j.rdc.2013.02.008Bucknor M.D., Gross A.J., Link T.M. Voriconazole-induced periostitis in two post-transplant patients. J Radiol Case Rep. 2013;7(8):10–17. DOI: 10.3941/jrcr.v7i8.1458Bucknor M.D., Gross A.J., Link T.M. Voriconazole-induced periostitis in two post-transplant patients. J Radiol Case Rep. 2013;7(8):10–17. DOI: 10.3941/jrcr.v7i8.1458Lucas-Fehm L.M., Makler P.T. Jr, Shapiro B. Technetium-99m MDP uptake in chronic venous insufficiency. Clin Nucl Med. 1986;11(11):803.Lucas-Fehm L.M., Makler P.T. Jr, Shapiro B. Technetium-99m MDP uptake in chronic venous insufficiency. Clin Nucl Med. 1986;11(11):803.Wendling D., Hafsaoui C., Laurain J.M., et al. Dysphagia and hypervitaminosis A: cervical hyperostosis. Joint Bone Spine. 2009;76(4):409–411. DOI: 10.1016/j.jbspin.2008.11.004Wendling D., Hafsaoui C., Laurain J.M., et al. Dysphagia and hypervitaminosis A: cervical hyperostosis. Joint Bone Spine. 2009;76(4):409–411. DOI: 10.1016/j.jbspin.2008.11.004Shakya P., Pokhrel K., Mlunde L.B., et al. Effectiveness of nonsteroidal anti-inflammatory drugs among patients with primary hypertrophic osteoarthropathy: A systematic review. J Dermatol Sci. 2018;90(1):21–26. DOI: 10.1016/j.jdermsci.2017.12.012Shakya P., Pokhrel K., Mlunde L.B., et al. Effectiveness of nonsteroidal anti-inflammatory drugs among patients with primary hypertrophic osteoarthropathy: A systematic review. J Dermatol Sci. 2018;90(1):21–26. DOI: 10.1016/j.jdermsci.2017.12.012DaCosta F.V., de Magalhães Souza Fialho S.C., Zimmermann A.F., et al. Infliximab treatment in pachydermoperiostosis: a rare disease without an effective therapeutic option. J Clin Rheumatol. 2010;16(4):183–184. DOI: 10.1097/rhu.0b013e3181df91c6DaCosta F.V., de Magalhães Souza Fialho S.C., Zimmermann A.F., et al. Infliximab treatment in pachydermoperiostosis: a rare disease without an effective therapeutic option. J Clin Rheumatol. 2010;16(4):183–184. DOI: 10.1097/rhu.0b013e3181df91c6Kikuchi R., Itoh M., Tamamushi M., et al. Hypertrophic Osteoarthropathy Secondary to Lung Cancer: Beneficial Effect of Anti-vascular Endothelial Growth Factor Antibody. J Clin Rheumatol. 2017;23(1):47–50. DOI: 10.1097/RHU.0000000000000441Kikuchi R., Itoh M., Tamamushi M., et al. Hypertrophic Osteoarthropathy Secondary to Lung Cancer: Beneficial Effect of Anti-vascular Endothelial Growth Factor Antibody. J Clin Rheumatol. 2017;23(1):47–50. DOI: 10.1097/RHU.0000000000000441

The authors declare that there are no conflicts of interest present.